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The viral envelope glycoprotein (GP) is thought to play important roles in the pathogenesis of ﬁlovirus
infection. It is known that GP expressed on the cell surface forms a steric shield over host proteins such
as major histocompatibility complex class I and integrin β1, which may result in the disorder of cell-to-
cell contacts and/or inhibition of the immune response. However, it is not clariﬁed whether this
phenomenon contributes to the pathogenicity of ﬁloviruses. In this study, we found that the steric
shielding efﬁciency differed among ﬁlovirus strains and was correlated with the difference in their
relative pathogenicities. While the highly glycosylated mucin-like region of GP was indispensable, the
differential shielding efﬁciency did not necessarily depend on the primary structure of the mucin-like
region, suggesting the importance of the overall properties (e.g., ﬂexibility and stability) of the GP
molecule for efﬁcient shielding of host proteins.
& 2013 Elsevier Inc. All rights reserved.Introduction
Filoviruses (viruses of the genera Marburgvirus and Ebolavirus
in the Family Filoviridae) are enveloped, negative-stranded RNA
viruses. Filovirus infection causes severe hemorrhagic fever in
human and non-human primates (Feldmann and Geisbert, 2011).
To date, there is one known species in the genus Marburgvirus
consisting of two distinct viruses, Marburg virus (MARV) and Ravn
virus. In contrast, ﬁve viruses (Ebola virus, Sudan virus, Taï Forest
virus, Bundibugyo virus, and Reston virus) are recognized within
the genus Ebolavirus, representing the distinct virus species, Zaire
ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus, Bundibugyo
ebolavirus, and Reston ebolavirus, respectively. Differential patho-
genicity has been suggested among ﬁloviruses (Geisbert and
Hensley, 2004; Mahanty and Bray, 2004). Ebola virus (EBOV)ll rights reserved.
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40, Japan.within the species Zaire ebolavirus is thought to be the most
pathogenic among the viruses in the genus Ebolavirus with case-
fatality rates up to 90%, whereas Reston virus has never caused
lethal infection in humans. Among Marburg viruses, the Angola
strain caused the largest outbreak with the highest case fatality
rate (90%) among Marburg viruses. While there was another
outbreak in Durba in 1998–2000 in which the case fatality rate
was 83% (Bausch et al., 2006), it is noted that in most of earlier
outbreaks of Marburg hemorrhagic fever case fatality rates did not
exceed 50% (Smith et al., 1982; Bausch et al., 2008), and that
macaques experimentally infected with the Angola strain died
after a rapidly progressive illness if compared with other viruses
such as the strain Musoke (Musoke) tested in the previous
experiments (Daddario-DiCaprio et al., 2006; Geisbert et al.,
2007). Thus, it could be suggested that the Angola strain is more
pathogenic than the Musoke strain, although statistically signiﬁ-
cant data are not available for the Musoke strain, due to low case
numbers. However, the molecular basis explaining the differential
pathogenicity of ﬁloviruses remains elusive, although previous
studies suggested that the viral envelope glycoprotein (GP) may
play important roles (Geisbert and Hensley, 2004; Matsuno et al.,
2010; Simmons et al., 2002; Takada et al., 2004; Yang et al., 2000).
Filovirus GP is the only spike protein and is responsible for
virus entry into host cells. EBOV and MARV GP undergoes
proteolytic cleavage by host proteases such as furin, resulting in
O. Noyori et al. / Virology 446 (2013) 152–161 153production of two subunits, GP1 and GP2, which are linked by a
single disulﬁde bond (Jeffers et al., 2002; Volchkov et al., 1998;
Volchkov et al., 2000). GP1 contains a putative receptor-binding
region and mucin-like region (MLR) that has a number of potential
N- and O-linked glycosylation sites (Dube et al., 2009; Kuhn et al.,
2006). GP2 has a transmembrane domain, cytoplasmic tail, and
internal fusion loop (Sanchez et al., 2007; Weissenhorn et al.,
1998).
Expression of EBOV GP in cultured cells results in loss of cell–
cell interaction as well as cell rounding and detachment of cells
from the substrate (Chan et al., 2000; Takada et al., 2000; Yang
et al., 2000). Though this can be observed in various types of cells,
the subsequent results of GP expression are different among cell
types (Simmons et al., 2002). While human cardiac microvascular
endothelial cells were reported to undergo anoikis and
detachment-mediated apoptosis upon GP expression (Ray et al.,
2004), transient expression of GP did not cause death in human
embryonic kidney 293T cells (Simmons et al., 2002).
GP-mediated downregulation of the host cell surface proteins
such as integrin β1 was proposed to be the molecular mechanism
for morphological changes of host cells (Simmons et al., 2002;
Takada et al., 2000). However, a recent study demonstrated that
these host proteins were indeed expressed but sterically masked
by GP on the cell surface (Francica et al., 2010). It was proposed
that the MLR of GP, which is highly glycosylated and spatially
occupies a very large region, formed a steric shield over host
proteins including integrin β1, major histocompatibility complex
class I (MHC I), and other immune molecules on the surface of
GP-expressing cells, which might result in abrogation of cell
adhesion and prevention of interaction between lymphocytes
and infected cells.
In this study, to investigate the possible contribution of GP-
mediated steric shielding to the pathogenicity of ﬁloviruses, we
compared the shielding effects among ﬁlovirus strains having
different pathogenicities and found a correlation between the
shielding effects and their pathogenic potential. In addition, we
mapped the GP regions responsible for the different shielding
effects observed among the viruses tested.Results
Comparison of the shielding effects between viruses of the genus
Ebolavirus
It has been demonstrated that the MLR forms a steric shield
over integrin β1 and MHC I on the surface of GP-expressing cells
(Francica et al., 2010). To compare this effect between viruses with
differential pathogenicity, HEK293T cells were transiently trans-
fected with plasmids expressing GP of a strain Mayinga-76 (Zaire)
or a strain Reston-89 (Reston) and analyzed by ﬂow cytometry
with probing antibodies to integrin β1 (MAB17-029) and MHC I
(Fig. 1). The steric shielding was expected to be observed as
decreased cell surface expression levels of these host proteins
due to the sterically hindered antibody access to the proteins. A
prominent shielding effect for integrin β1 was observed on Zaire
GP-expressing cells compared with that of Reston GP (Fig. 1A, left
panel). On the other hand, MHC I was comparably shielded by
Zaire and Reston GPs and this molecule was almost undetectable
on the cells expressing these GPs (Fig. 1B). We quantiﬁed the
expression levels of both host proteins by calculating the relative
means of ﬂuorescence intensity (MFI) and conﬁrmed the signiﬁ-
cantly different shielding effects between Zaire and Reston GPs
(Fig. 1C). It should be noted that integrin β1 was detected normally
on the surface of GP-expressing cells when cells were stained with
another antibody (MAB1965) whose epitope is likely differentfrom that of MAB17-029 (Fig. 1A, right panel), conﬁrming that the
reduced detection level of cell surface integrin β1 by MAB17-029
was not due to reduced expression (i.e., down-regulation) of this
molecule. Furthermore, we conﬁrmed by Western blotting that
overall intracellular expression levels of these host proteins were
not affected by the expression of GPs (Fig. 1D).
Comparison of the shielding effects between MARV strains
To examine whether the shielding effect was similarly observed
upon MARV GP expression, we selected two strains, Angola and
Musoke, which likely have differential pathogenicity for humans
and nonhuman primates (Daddario-DiCaprio et al., 2006; Geisbert
et al., 2007). These MARV GPs also shielded integrin β1 and MHC I
molecules on cell surfaces, suggesting that the steric shielding
effect is a common phenomenon in ﬁlovirus GP-expressing cells
(Fig. 2A, B, and C). Consistent with the expression of Zaire and
Reston GPs, the MHC I molecule was more markedly shielded than
integrin β1. Interestingly, Angola GP showed more prominent
shielding effects for both proteins than Musoke GP. Similarly to
Zaire and Reston GP-expressing cells, intracellular expression
levels of these host proteins were not affected by the expression
of MARV GPs (Fig. 2D).
Role of the MLR structure in the steric shielding
To ascertain whether the highly glycosylated MLR played an
essential role for GP-mediated shielding effects, we constructed
MLR-deletion mutant GPs (ZΔmuc and AΔmuc) and analyzed their
shielding effects by comparing them with the respective wild-type
GPs. As expected, reduced shielding effects were observed on the
cells expressing MLR-deletion GPs (Fig. 3). We then focused on the
role of the MLR in different shielding effects between ﬁlovirus strains.
Amino acid sequence comparison between Zaire and Reston GPs
indicates that the similarity of their MLRs is approximately 16%.
Although there is a relatively high amino acid similarity bet-
ween Angola and Musoke GPs (86%), the numbers of potential
O-glycosylation sites vary between these GPs (i.e., Angola GP has
more potential O-glycosylation sites than Musoke GP), suggesting
that the steric shielding effect is potentially dependent on the
primary structure of the MLR. To address this hypothesis, we
constructed chimeric mutant GPs whose MLRs were swapped
between viruses (ZRZ, RZR, AMA, and MAM) (Fig. 4A and B) and
analyzed their shielding effects together with wild-type GPs (Fig. 4C
and D). As compared with wild-type Zaire GP, slightly decreased and
comparable effects for integrin β1 and MHC I, respectively, were
observed on cells expressing ZRZ. Unexpectedly, only small shielding
effects on integrin β1 and MHC I were observed on cells expressing
RZR. Similarly, swapping of the MLR of MARV GPs (AMA and MAM)
did not reverse the phenotype. Taken together, these results indi-
cated that the MLR was required for efﬁcient steric shielding, but its
primary structure was not essential for the differential effects
between Zaire and Reston or Angola and Musoke GPs.
Identiﬁcation of the GP region required for efﬁcient steric shielding
To further investigate which region of GP was involved in the
efﬁciency of steric shielding, chimeric mutants between Zaire and
Reston GPs (ZZR, ZRR, RRZ, and RZZ) or Angola and Musoke GPs
(AAM, AMM, MMA, andMAA) were constructed (Fig. 5A and B). Then
the efﬁciency of steric shielding caused by these mutant GPs was
compared with the condition in wild-type GPs (Fig. 5C and D). While
ZZR showed a shielding effect on integrin β1 as strong as that of wild-
type Zaire GP, the other chimeric mutants between Zaire and Reston
GPs showed comparable or lesser shielding effects compared to wild-
type Reston GP. MHC I was almost undetectable on cells expressing
Fig. 1. Differential steric shielding efﬁciency between Zaire and Reston GPs. 293T cells transfected with pCAGGS expressing wild-type Zaire GP, Reston GP, or pCAGGS alone
(Vector) were stained for integrin β1 (MAB17-029 or MAB1965) (A) or MHC I (B) and analyzed by ﬂow cytometry. Data are representative of ﬁve independent experiments. To
quantify the shielding effects, the relative mean ﬂuorescence intensity (MFI) of detected host proteins was calculated according to the formula [(MFI of GP expressing cells
MFI of unstained cells)/(MFI of vector transfected cellsMFI of unstained cells)100] (C). Bars represent the averages of MFI and standard deviations of ﬁve independent
experiments. Statistical signiﬁcance was determined using Student′s t-test (*, Po0.05). Intracellular expression levels of integrin β1 and MHC I were examined by Western
blotting (D).
O. Noyori et al. / Virology 446 (2013) 152–161154these chimeric mutant GPs (ZZR, ZRR, RRZ, and RZZ) as was the case
with wild-type Zaire and Reston GPs. On the other hand, all chimeric
mutant MARV GPs with the GP2C region (Matsuno et al., 2010)
derived from Angola GP (i.e., AMA, MAA, and MMA) had shielding
effects on both proteins that were as efﬁcient as wild-type Angola GP,
indicating that the MARV GP2C region played a critical role in the
optimal steric shielding effect.
Importance of the amino acid residue at position 547 for the efﬁcient
steric shielding by MARV GP
Since the difference between MARV GPs was more prominent
in the shielding effect, albeit with a much smaller amino acidsequence difference than between Zaire and Reston GPs, we then
sought to identify the amino acid residues responsible for the
differential ability to produce steric shielding between Angola and
Musoke GPs. There are four different amino acids in the GP2C
region between Angola and Musoke GPs. We constructed eight
mutant GPs containing a single-amino acid substitution: four
Angola-based mutant GPs (A/H504Y, A/G547V, A/A596T, and A/
R618K) and four Musoke-based mutant GPs (M/Y504H, M/V547G,
M/T596A, and M/K618R) (Fig. 6A and B). The shielding effects of
these mutant GPs were compared (Fig. 6C and D). All Angola-
based mutant GPs showed shielding effects comparable to that of
wild-type Angola GP. Similarly, amino acid substitutions at posi-
tions 504, 596, and 618 in Musoke-based mutant GP (M/Y504H,
Fig. 2. Differential steric shielding efﬁciency between Angola and Musoke GPs. 293T cells transfected with pCAGGS expressing wild-type Angola GP or Musoke GP, or
pCAGGS alone (Vector) were stained for integrin β1 (MAB17-029 or MAB1965) (A) or MHC I (B) and analyzed by ﬂow cytometry. Data are representative of four independent
experiments. MFI and statistical signiﬁcance were analyzed (C) as described in the legend of Fig. 1 (n, Po0.05; nn, Po0.01). Intracellular expression levels of integrin β1 and
MHC I were examined by Western blotting (D).
O. Noyori et al. / Virology 446 (2013) 152–161 155M/T596A, and M/K618R, respectively) did not affect their steric
shielding abilities. Interestingly, however, the substitution at
position 547 of Musoke GP (M/V547G) resulted in an enhanced
shielding effect comparable to that of wild-type Angola GP.Discussion
Many viruses have developed strategies to evade host immu-
nity. One of the well-documented mechanisms is interference with
the expression of host proteins involved in immune reactions.
For example, adenovirus E19 protein prevents MHC I transport to
the plasma membrane (Andersson et al., 1985). Cell surface
MHC I molecules are internalized upon expression of some viral
proteins such as human immunodeﬁciency virus Nef and Kaposi′ssarcoma-associated herpesvirus/human herpesvirus-8 K3/K5 pro-
teins (Blagoveshchenskaya, et al., 2002; Ishido et al., 2000), which
might result in reduced contact with cytotoxic T lymphocytes.
Similarly, it was recently shown that interaction between MHC I
and T-cell receptors was blocked upon EBOV GP expression
(Francica et al., 2010). Furthermore, morphological changes
(i.e., cell rounding, detachment from the culture dish) induced
by dysfunction of cellular adhesion proteins (e.g., integrins) are
observed in GP-expressing cells (Chan et al., 2000; Simmons et al.,
2002; Takada et al., 2000; Yang et al., 2000). These morphological
changes are consistently observed in cells expressing GPs of
viruses within all known ﬁlovirus species (unpublished data) and
indeed also in EBOV-infected cells (Alazard-Dany et al., 2006).
These phenomena caused by EBOV GP expression are likely due to
a distinctive mechanism called “steric shielding” that was recently
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Fig. 3. Reduced steric shielding efﬁciency after the deletion of the MLR. The names of the mutant GPs and relevant amino acid positions are shown in the schematic (A and B,
upper). 293T cells transfected with pCAGGS expressing wild-type Zaire GP, Angola GP, ZΔmuc, AΔmuc, or pCAGGS alone (Vector) were stained for integrin β1 (MAB17-029)
or MHC I and analyzed by ﬂow cytometry (A and B, lower). Data are representative of 4 or more independent experiments. MFI (C and D) and statistical signiﬁcance was
analyzed as described in the legends of Figs. 1 and 2.
O. Noyori et al. / Virology 446 (2013) 152–161156proposed (Francica et al., 2010; Reynard et al., 2009). The present
study further indicated that this GP function was common in
ﬁloviruses, including MARV.
It is well documented that the MLR of EBOV GP plays a critical
role in the morphological changes of GP-expressing cells, likely
caused by steric shielding effects (Francica et al., 2009; Simmons
et al., 2002; Sullivan et al., 2005; Takada et al., 2000; Yang et al.,
2000). It was also reported that the MLR and sugar chains on the GP
molecule were important for epitope shielding, suggesting that the
MLR plays a crucial role in the steric shielding effect (Francica et al.
2010; Reynard et al., 2009). Since amino acid sequences of the MLR
vary among ﬁloviruses, we initially assumed that the difference in
the steric shielding effects observed among ﬁloviruses was due, at
least in part, to the difference of amino acid sequences and glycan
structures in the MLR of GPs. However, contrary to our expectation,
the shielding effect was not simply dependent on the primary
structure of MLR itself. Our data obtained with chimeric mutant GPs
suggested the importance of the overall properties (e.g., glycosyla-
tion pattern, ﬂexibility, and/or stability) of the GP molecule for the
efﬁciency of steric shielding for host proteins.
In MARV GP, we found that the amino acid residue at position
547 in GP2 was important for the efﬁciency of the steric shielding.Since glycine at 547 is presumed to form a stable αβ strand
included in the internal fusion loop that wraps around the outside
of the GP trimer, it may affect the ﬂexibility of GP and/or the
efﬁciency of conformational change as discussed previously
(Harrison et al., 2012; Matsuno et al., 2010). Interestingly, GP
mutants, AAM and A/G547V, also showed shielding effects com-
parable to that of wild-type Angola GP despite their amino acid at
the position of 547 being derived from Musoke, suggesting
another important factor(s) for the higher shielding capacity of
Angola GP. It has been shown that EBOV GP1 has a glycan cap
containing N-glycans in the GP1 head subdomain (Lee et al., 2008).
Since this domain is fully exposed on the upper and outer surfaces
of GP1, it could also be assumed that these conformations, as well
as the GP2 region, contribute signiﬁcantly to the high shielding
efﬁciency. If Angola GP also has a domain with a similar function, it
might compensate for the negatively affecting substitutions in
these mutant GPs (i.e., AAM and A/G547V). Structural information
on MARV GP may be needed to fully understand the determinants
for the differential shielding efﬁciency between MARVs.
As shown in Figs. 1 and 2, GPs of all ﬁloviruses tested masked
MHC I more efﬁciently than integrin β1. Although epitopes of probing
antibodies might be one of the primary factors as shown by the
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Fig. 4. Limited effects of MLR swapping on the shielding efﬁciency. Names of the mutant GPs and relevant amino acid positions are shown in the schematic (A and B). 293T
cells transfected with wild-type GPs, chimeric mutant GPs, or pCAGGS alone (Vector) were stained for integrin β1 (MAB17-029) or MHC I and analyzed by ﬂow cytometry
(C and D). Data are representative of 4 or more independent experiments. MFIs (E and F) were analyzed as described in the legends of Figs. 1 and 2. Statistical signiﬁcance
was analyzed for integrin β1 (n, Po0.05; nn, Po0.01).
O. Noyori et al. / Virology 446 (2013) 152–161 157differential recognition of integrin β1 between MAB17-029 and
MAB1965, the efﬁciency of steric shielding was presumed to also
be affected by the molecular size of the host protein. Indeed, MHC I
consisting of two polypeptide chains, α and β2-microglobulin (45 and
12 kDa, respectively), is much smaller than integrin β1 (130 kDa). To
investigate this hypothesis, we tested another adhesion molecule,
CD151 (32 kDa). However, all tested GPs showed only moderate
shielding effects for CD151, despite this molecule having smaller
molecular weight than MHC I (data not shown), suggesting that
other factors might be involved in the efﬁciency of steric shielding.
Since EBOV and MARV GPs might be compartmentalized in the lipid
raft during viral assembly and budding (Bavari et al., 2002), host
proteins colocalized with GP in the lipid raft are expected to be
masked predominantly. Accordingly, MHC I is expressed in the lipid
raft in some cell lines (e.g., uveal melanoma and malignant variant of
DAC) (Bene et al., 2004; Wadehra et al., 2003). On the other hand,
tetraspanins including CD151 form microdomains known as
tetraspanin-enriched microdomains, which are different from the
lipid raft (Blumenthal et al., 2012). These reports may support ourhypothesis that the GP-mediated shielding efﬁciency is dependent on
not only molecular size but also the localization of host proteins.
Previously, it was shown that the expression levels of GP were
tightly controlled in infected cells and cytotoxic effects occurred
late in infection (Alazard-Dany et al., 2006; Volchkov et al., 2001).
Moderate expression levels of GP did not affect the surface
expression of MHC I and integrin β1 (Alazard-Dany et al., 2006).
Thus, it might be possible that GP-mediated steric shielding may
be only observed when GP is expressed at high density on the cell
surface. In addition, a recent report suggests that GP is not the sole
determinant for the different pathogenicity between Zaire and
Reston viruses and other viral proteins also play a signiﬁcant role
(Groseth et al., 2012). Further studies with reverse genetics
approaches using infectious recombinant viruses should be
needed to clarify the importance of the steric shielding effect in
the pathogenesis in infected animals.
In this study, we demonstrated the differential capacity to form
steric shielding among ﬁlovirus GPs, which might be correlated
with their different pathogenicities. It should be noted that Zaire
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Fig. 5. Importance of the GP2 region of MARV GP for efﬁcient steric shielding. Names of the mutant GPs and relevant amino acid positions are shown in the schematic (A and
B). 293T cells transfected with wild-type GPs or chimeric mutant GPs, or pCAGGS alone (Vector) were stained for integrin β1 (MAB17-029) or MHC and analyzed by ﬂow
cytometry (C and D). Data are representative of 4 or more independent experiments. MFIs (E and F) were analyzed as described in the legends of Figs. 1 and 2. Statistical
signiﬁcance was analyzed for integrin β1 (n, Po0.05; nn, Po0.01).
O. Noyori et al. / Virology 446 (2013) 152–161158and Reston GPs showed differential efﬁciency in cell rounding of
macrophages (Simmons et al., 2002) which are the major target
cells whose infection might be directly involved in the pathogen-
esis of ﬁlovirus infection (Davis et al., 1997; Geisbert and Hensley,
2004; Schnittler and Feldmann, 1999). If GP-mediated steric
shielding plays important roles in the evasion of host immuneresponses initiated by the various signaling factors mounting
correct host responses (e.g., Fas, CD80, and CD86), it may be one
of the critical determinants for the pathogenesis of ﬁlovirus
infection. Thus, it is necessary to clarify the importance of the
shielding those signaling factors on immune cells such as macro-
phages and dendritic cells.
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Plasmids
For GP expression, cDNAs encoding full-length GPs of strains
Mayinga-76 (Zaire), Reston-89 (Reston), Angola, and Musoke wereused. By using the primers containing the desired sequences and
the class IIS restriction enzyme (BsmBI), the MLR-deletion mutant
(ZΔmuc and AΔmuc), chimeric GP constructs (ZZR, ZRR, RRZ, RZZ,
AAM, AMM, MMA, and MAA), and mutant GPs with a single
substitution (A/H504Y, A/G547V, A/A596T, A/R618K, M/Y504H,
M/V547G, M/T596A, and M/K618R) were generated as described
O. Noyori et al. / Virology 446 (2013) 152–161160previously (Matsuno et al., 2010). Wild-type and all mutant GPs
were cloned into the mammalian expression plasmid pCAGGS and
then used for transfection. All cloned genes were sequenced to
ensure that no errors were introduced.
Transfection
Human embryonic kidney 293T cells were maintained in
Dulbecco′s modiﬁed Eagle′s medium (DMEM) (Gibco) supplemen-
ted with 10% fetal bovine serum and penicillin/streptomycin at
37 1C with 5% CO2. 293T cells were plated in 6-well plates one day
before transfection. Cells were transfected with 2 μg of plasmids
by TransIT (Mirus) according to the manufacturer′s directions. For
analyses of the shielding effects of wild-type Zaire, Reston, and
their mutant GPs, cells were cotransfected with 2 μg of plasmids
encoding enhanced green ﬂuorescent protein (eGFP) and GPs. For
analyses of the shielding effects of MARV GPs, cells were trans-
fected with plasmids encoding wild-type or mutant MARV GPs.
Forty hours posttransfection, cells were collected, washed once in
FACS buffer (0.5% FCS and 0.05% sodium azide in PBS), and used for
ﬂow cytometric analyses.
Monoclonal antibodies to GPs
A mouse monoclonal antibody (MAb) 42/3.7 (IgG1) that broadly
binds to GP of all known viruses within the genus Ebolavirus
(Nakayama et al., 2010), ZGP662/1.1 (IgG2a), which recognizes
amino acid positions 171–190 (YRGTTFAEGVVAFLILPQAK) in GP1 of
Zaire GP (Takada et al., 2007), MARV GP-speciﬁc mouse monoclonal
antibody MGP14-22 (IgG1), which recognizes amino acid positions
445–465 (FPFLDGLINAPIDFDPVPNTK) on GP2, and AΔM16-2-13
(IgM) (Kajihara et al., 2012) were generated according to a standard
procedure reported previously (Takada et al., 2001; Nakayama et al.,
2011), and puriﬁed from mouse ascites using protein A agarose
columns (Bio-Rad). Puriﬁed MGP14-22 was labeled with Alexa Fluor
488 using an Alexa Fluor 488 Protein Labeling Kit (Invitrogen).
Flow cytometry
For detection of integrin β1 and MHC I, APC-conjugated anti-
human integrin β1 antibody MAB17-029 (eBioscience) and PE-
Cy5-conjugated anti-human HLA-ABC antibody (eBioscience) were
used, respectively. Cells were incubated on ice with these anti-
bodies for 30 min. To detect integrin β1 on GP-expressing cells,
MAb MAB1965 (Chemicon) was also used. Transfected cells were
washed three times with FACS buffer and then incubated on ice for
30 min with Alexa 647-labeled goat anti-mouse IgG (Invitrogen).
To gate Zaire and Reston GP-expressing cells, we ﬁrst tried to stain
the cells with MAb ZGP42/3.7, which recognizes an epitope shared
by Zaire and Reston GPs (Nakayama et al., 2010). However, Zaire
and Reston GPs were stained differently (i.e., the reactivity to Zaire
GP was lower than that to Reston GP), most likely due to self-
shielding effects against the epitope on GP (Francica et al., 2010),
which might be different between Zaire and Reston GPs. Thus,
293T cells were cotransfected with plasmids each expressing eGFP
or GP (Zaire or Reston), and GP-expressing cells were analyzed by
gating the GFP-positive cells. To verify that eGFP-positive cells also
express GP, cells transfected with these plasmids in the same
conditions were stained with MAbs (ZGP746/16.2 or ZGP42/3.7)
(Takada et al., 2007), and we conﬁrmed that at least 70% of cells
expressing eGFP also expressed GP. On the other hand, MARV
(Angola and Musoke) GPs were similarly stained on the cells by
using MAb MGP14-22, and GP-positive cells were gated for the
detection of integrin β1 and MHC I, with the exception of staining
of MARV GP-expressing cells with MAb MAB1965. For these cells,
GFP-positive cells were gated following cotransfection witheGFP- and MARV GP-expressing plasmids (Fig. 2A, right panel).
Following gating viable cells by forward and side scatter, 7000 to
10,000 eGFP-gated or 4000 to 7000 GP-gated events were accu-
mulated and analyzed for the detection of integrin β1 and MHC I
with Becton Dickinson FACS Canto and FlowJo software (Tree
Star, Inc.).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting
Expression levels of wild-type and mutant GPs in transfected
cells were veriﬁed by SDS-PAGE and Western blotting (Supple-
mentary Fig. S1). Cells expressing GP were lysed with Laemmli
sample buffer (Bio-Rad) and the insoluble fractionwas removed by
centrifugation. Solubilized proteins were separated by SDS-PAGE,
and blotted on a polyvinylidene diﬂuoride (PVDF) membrane
(Millipore). Non-speciﬁc binding to the membrane was blocked
with 3% skim milk in PBS. ZGP42/3.7, MGP14-22, ZGP662/1.1,
AΔM16-2-13, and an anti-β-actin antibody (AC-15; Abcam) were
used as primary antibodies. The bound antibodies were detected
with peroxidase-conjugated goat anti-mouse IgG (H+L) (Jackson
Immuno Research), or anti-mouse IgM (Kirkegaard & Perry
Laboratories) followed by visualization with Immobilon Western
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